Catherine M Lee

54222613, Jun 6, 1995

Apr 16, 1993

8/049015

Catherine T. Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco cyn CA
Tan T. Dinh - Garden Grove CA

Baxter International Inc. - Deerfield IL

C12N 950
C12N 948
C12N 500
A61K 3762

435219

Proteolytic enzyme compositions and processes for digesting connective tissue are disclosed. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The enzyme compositions preferably contain an aqueous mixture of collagenase having an activity of about 43 nkat/ml to about 51 nkat/ml, and chymopapain having an activity of about 0. 22 nkat/ml to about 0. 44 nkat/ml.

53325036, Jul 26, 1994

Apr 16, 1993

8/073272

Catherine Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco Cyn. CA
Tan T. Dinh - Garden Grove CA

Baxter International Inc. - Deerfield IL

B01D 1508

210635

A process for purifying crude collagenase is disclosed. The collagenase purification process includes providing a stabilized crude collagenase solution containing collagenase, pigment, toxins, bacterial materials, and proteolytic enzyme impurities including clostripain, trypsin, and caseinase. The stabilized collagenase solution is applied to hydroxylapatite packing. pigment and caseinase are eluted with a first solution comprising about 0. 05 M to about 0. 3 M phosphate buffer, and then collagenase, trypsin, and clostripain are eluted with a second solution comprising about 0. 35 M to about 0. 5 M phosphate buffer to provide a first collected solution. The first collected solution is then applied to gel filtration packing and collagenase and clostripain are eluted with a neutral pH buffer solution, to provide a second collected solution. The second collected solution is then applied to Reactive Red 120-Agarose packing and collagenase is eluted with a neutral pH buffer solution to provide purified collagenase. The process provides extremely pure collagenase in high yield with reduced consumption of eluting solutions and avoids unpredictable gradient eluting techniques.

54242088, Jun 13, 1995

Sep 23, 1994

8/311383

Catherine T. Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco Cyn CA
Tan T. Dinh - Garden Grove CA

Baxter International Inc. - Deerfield IL

C07G 1500
C12N 500
C12N 100
C12N 950

435268

Proteolytic enzyme compositions and processes for digesting connective tissue are provided. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The composition preferrably contains collagenase having an activity of about 43 nkat/ml to about 51 nkat/ml and chymopapin having an activity of about 0. 22 nkat/ml to about 0. 44 nkat/ml.

56703589, Sep 23, 1997

Oct 19, 1995

8/545439

Catherine T. Lee - Laguna Hills CA
Cynthia Zerfass - Trabuco Canyon CA
Tan Thanh Dinh - Garden Grove CA
Minh T. Ma - Santa Ana CA

Baxter International Inc. - Deerfield IL

C12N 948
C07G 1700
C07G 1500

435212

The activities of chymopapain or papain in enzyme mixtures are inhibited by the addition of glycogen, hyaluronic acid, or desulfated heparin. The process for isolating viable hepatocytes or pancreatic cells by treatment with papain or chymopapain is improved by terminating the treatment by inhibiting the reaction with these polysaccharides. Similarly, the process for removing undesired tissue by treatment with papain or chymopapain is improved by terminating the treatment by inhibiting the reaction with these polysaccharides.

60082925, Dec 28, 1999

Dec 2, 1997

8/982846

Catherine Ting Lee - Laguna Hills CA
Jun Yang - Dove Canyon CA
Tan Thanh Dinh - Fountain Valley CA
Ernest H. Pfadenhauer - Costa Mesa CA

Baxter International Inc. - Deerfield IL

A61L 2700

525 541

A method for preparing collagenous biological tissues for use as implantable bioprosthetic material, and articles prepared thereby. The method generally comprises the steps of a) contacting the tissue with an aldehyde fixative to effect cross-linking of the connective tissue protein(s) and subsequently b) contacting the tissue with a polyglycidyl ether. The treatment of the crosslinked tissue with the polyglycidyl ether serves to mitigate the tissue's propensity to undergo calcification following implantation in the body.

58911960, Apr 6, 1999

Apr 16, 1997

8/843504

Catherine Ting Lee - Laguna Hills CA
Jun Yang - Dove Canyon CA

Baxter International Inc. - Deerfield IL

A61L 1700

8 9411

Methods for binding heparin to biological or synthetic materials which are to be implanted within a mammalian body. In instances where connective tissue proteins or other components of the material having adequate carboxyl groups present thereon, the method comprises a) contacting the material with a carboxyl-activating agent, b) contacting the material with a polyamine compound to form amide-bound polyarnine side chains at the sites of the previously activated carboxyl groups, and c) contacting the material with heparin such that heparin will become bound to the amino groups on the polyamine side chains. In other applications wherein the connective tissue proteins or other molecular entities of the material are devoid of or deficient in carboxyl groups, the method will comprise a) contacting the material with a carboxyl-activating agent in combination with a polyamine compound which has functional carboxyl groups thereon such that at least some of the functional carboxyl groups of the polyamine compound will become activated and will react with some of the amino groups on the polyamine compounds to form a polyamine network interlocked within the molecular structure of the material, and b) contacting the material with heparin such that heparin will become bound to amino groups on the polyamine network.